Rapport Therapeutics
Rapport Reveals Promising Phase 2a Data for RAP-219 Epilepsy Pill, Plans Phase 3 Trials
Rapport Therapeutics; RAP-219; epilepsy; seizure reduction; Phase 2a clinical trial; focal onset seizures; Phase 3 trials; anti-seizure medication; drug-resistant epilepsy; clinical development
Rapport Therapeutics Faces Regulatory Hurdles in Pain Treatment Trials
Rapport Therapeutics, pain treatment trials, regulatory challenges, RAP-219, clinical development